# Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Biotech Innovator with Over 63% Potential Upside

- Link: https://www.directorstalkinterviews.com/soleno-therapeutics-inc-slno-stock-analysis-biotech-innovator-with-over-63-potential-upside/4121212549
- Published: 2025-08-18T10:44:36+01:00
- Author: Madison Wilson

Investors with an eye on the healthcare sector might find Soleno Therapeutics, Inc.(
SLNO) an intriguing opportunity. The company, headquartered in Redwood City, California,
operates within the biotechnology industry and focuses on developing novel therapeutics
for rare diseases. With a market capitalization of $3.81 billion, Soleno is gaining
attention not only for its innovative clinical-stage developments but also for its
significant stock potential.

Soleno’s flagship product, the Diazoxide Choline Extended-Release tablets, is in
Phase III clinical trials aimed at treating Prader-Willi Syndrome, a genetic disorder
characterized by excessive appetite and obesity. This focus positions Soleno at 
the cutting edge of addressing unmet medical needs in rare diseases.

Currently, Soleno’s stock is trading at $71.63, reflecting a recent price change
of -0.07%. Despite this minor decline, the stock shows a promising 52-week range
from $42.54 to $88.49, indicating substantial volatility but also potential for 
upward movement. The company’s technical indicators present a mixed picture, with
a 50-day moving average of $82.72 and a 200-day moving average of $63.29. The Relative
Strength Index (RSI) stands at 44.47, suggesting that the stock is approaching oversold
territory, which could potentially signal a buying opportunity for investors.

The financials reveal some challenges, typical for a clinical-stage biopharmaceutical
company, with no available revenue growth figures and an EPS of -4.22. Additionally,
the return on equity is a concerning -69.53%, and the company reports a negative
free cash flow of approximately $22.9 million. However, Soleno does not currently
offer a dividend yield, maintaining a payout ratio of 0.00%, indicating that any
available capital is likely reinvested into its development pipeline.

Despite these financial hurdles, the market sentiment around Soleno is notably optimistic.
Analysts have issued nine buy ratings with no hold or sell recommendations. The 
target price range for SLNO is set between $100.00 and $145.00, with an average 
target price of $117.00. This reflects a potential upside of 63.34%, signaling strong
confidence in Soleno’s future growth prospects, particularly linked to the success
of its lead product candidate.

For individual investors, the allure of Soleno Therapeutics lies in its high-risk,
high-reward scenario. The company’s advancements in treating rare diseases, particularly
through its Phase III trials, could revolutionize its financial outlook and stock
performance. However, investors should weigh these prospects against the inherent
risks associated with investing in biotechnology firms, especially those in the 
clinical trial phase. As always, conducting thorough due diligence and considering
one’s risk tolerance is essential when contemplating an investment in Soleno Therapeutics,
Inc.

Share on:
